Are CSF or serum ganglioside antibodies related to peripheral nerve demyelination in neuroborreliosis, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy?

1992 ◽  
Vol 242 (2-3) ◽  
pp. 122-126 ◽  
Author(s):  
Michael Weller ◽  
Andreas Stevens ◽  
Norbert Sommer ◽  
Horst Wiethölter
Keyword(s):  
Peripheral Nerve ◽  
Chronic Inflammatory Demyelinating Polyradiculoneuropathy ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Ganglioside Antibodies ◽  
Guillain Barré

scholarly journals Autoantibody screening in Guillain–Barré syndrome

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Cinta Lleixà ◽  
Lorena Martín-Aguilar ◽  
Elba Pascual-Goñi ◽  
Teresa Franco ◽  
Marta Caballero ◽  
...  
Keyword(s):  
Peripheral Nerve ◽  
Motor Neurons ◽  
Prognostic Value ◽  
Nerve Tissue ◽  
Guillain Barre Syndrome ◽  
Drg Neurons ◽  
Guillain Barré Syndrome ◽  
Ganglioside Antibodies ◽  
Human Motor ◽  
Guillain Barré

Abstract Background Guillain–Barré syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presentation. Although some evidences support the role of autoantibodies in its pathogenesis, the target antigens remain unknown in a substantial proportion of GBS patients. The objective of this study is to screen for autoantibodies targeting peripheral nerve components in Guillain–Barré syndrome. Methods Autoantibody screening was performed in serum samples from all GBS patients included in the International GBS Outcome study by 11 different Spanish centres. The screening included testing for anti-ganglioside antibodies, anti-nodo/paranodal antibodies, immunocytochemistry on neuroblastoma-derived human motor neurons and murine dorsal root ganglia (DRG) neurons, and immunohistochemistry on monkey peripheral nerve sections. We analysed the staining patterns of patients and controls. The prognostic value of anti-ganglioside antibodies was also analysed. Results None of the GBS patients (n = 100) reacted against the nodo/paranodal proteins tested, and 61 (61%) were positive for, at least, one anti-ganglioside antibody. GBS sera reacted strongly against DRG neurons more frequently than controls both with IgG (6% vs 0%; p = 0.03) and IgM (11% vs 2.2%; p = 0.02) immunodetection. No differences were observed in the proportion of patients reacting against neuroblastoma-derived human motor neurons. Reactivity against monkey nerve tissue was frequently detected both in patients and controls, but specific patterns were only detected in GBS patients: IgG from 13 (13%) patients reacted strongly against Schwann cells. Finally, we confirmed that IgG anti-GM1 antibodies are associated with poorer outcomes independently of other known prognostic factors. Conclusion Our study confirms that (1) GBS patients display a heterogeneous repertoire of autoantibodies targeting nerve cells and structures; (2) gangliosides are the most frequent antigens in GBS patients and have a prognostic value; (3) further antigen-discovery experiments may elucidate other potential antigens in GBS.

Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain–Barré syndrome

2005 ◽  
Vol 161 (1-2) ◽  
pp. 183-189 ◽  
Author(s):  
Karin Geleijns ◽  
Jon D. Laman ◽  
Wouter van Rijs ◽  
Anne P. Tio-Gillen ◽  
Rogier Q. Hintzen ◽  
...  
Keyword(s):  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Ganglioside Antibodies ◽  
Guillain Barré

scholarly journals Recurrent Guillain-Barré Syndrome with Anti-GT1a and Anti-GQ1b Ganglioside Antibodies

2019 ◽  
Vol 15 (3) ◽  
pp. 404
Author(s):  
Jihyeon Hwang ◽  
Ye-Ji Kwon ◽  
Jong Kuk Kim ◽  
Nam Jun Kim ◽  
Seol-Hee Baek
Keyword(s):  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Ganglioside Antibodies ◽  
Guillain Barré ◽  
Gq1b Ganglioside

Electrophysiological features of Guillain–Barre syndrome associated with anti-galactocerebroside antibodies as well as anti-ganglioside antibodies

2014 ◽  
Vol 275 (1-2) ◽  
pp. 9
Author(s):  
Susumu Kusunoki ◽  
Makoto Samukawa ◽  
Yukihiro Hamada ◽  
Motoi Kuwahara ◽  
Kazuo Takada ◽  
...  
Keyword(s):  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Ganglioside Antibodies ◽  
Guillain Barré

Electrophysiological assessment of Guillain-Barré syndrome with both Gal-C and ganglioside antibodies; tendency for demyelinating type

2016 ◽  
Vol 301 ◽  
pp. 61-64 ◽  
Author(s):  
Makoto Samukawa ◽  
Motoi Kuwahara ◽  
Miyuki Morikawa ◽  
Rino Ueno ◽  
Yukihiro Hamada ◽  
...  
Keyword(s):  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Ganglioside Antibodies ◽  
Guillain Barré

scholarly journals Role of Anti-ganglioside Antibodies in the Diagnosis of Guillain-Barré Syndrome as an Alternate Investigation

Cureus ◽  
2019 ◽  
Author(s):  
Muhammad Luqman Saeed ◽  
Behzad Kaleem Baloch ◽  
Syed Nayer Mahmud ◽  
Muhammad Tariq Khan ◽  
Muhammad Shoaib Safdar Qureshi ◽  
...  
Keyword(s):  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Ganglioside Antibodies ◽  
Guillain Barré

scholarly journals Treatment-related fluctuation in Guillain-Barre syndrome

2011 ◽  
Vol 02 (02) ◽  
pp. 168-170 ◽  
Author(s):  
Thirunavukkarasu Thivakaran ◽  
Ranjanie Gamage ◽  
Inuka Kishara Gooneratne
Keyword(s):  
Immune Activation ◽  
Early Treatment ◽  
Disease Onset ◽  
Immunoglobulin Therapy ◽  
Chronic Inflammatory Demyelinating Polyradiculoneuropathy ◽  
Guillain Barre Syndrome ◽  
Disability Scale ◽  
Guillain Barré Syndrome ◽  
Immunoglobulin Treatment ◽  
Guillain Barré

ABSTRACTGuillain-Barre syndrome (GBS) is usually a monophasic illness but relapses occur. A 55-year-old female with hypertension and vitiligo presented with acute inflammatory demyelinating polyradiculoneuropathy. She improved with immunoglobulin treatment started on day 6 of illness, but relapsed on day 14 warranting repeat immunoglobulin therapy. Thereafter recovery was complete. Her relapse was due to treatment-related fluctuation (TRF). TRF is improvement in the GBS disability scale of at least one grade after completion of immunotherapy followed by worsening of the disability scale of at least one grade within the first 2 months after disease onset. Recurrent GBS and chronic inflammatory demyelinating polyradiculoneuropathy were excluded. During the peak of the illness ANA titres were transiently high. The presence of other medical conditions, predominant proximal weakness and the absence of preceding diarrhea are predictors for TRF seen in this patient. Early treatment and evidence of ongoing immune activation have contributed toward TRF.

Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Pregnancy

2018 ◽  
Author(s):  
Pariwat Thaisetthawatkul ◽  
Eric Logigian
Keyword(s):  
Fetal Outcome ◽  
Chronic Inflammatory Demyelinating Polyradiculoneuropathy ◽  
Guillain Barre Syndrome ◽  
Progressive Muscle Weakness ◽  
Immune Mediated ◽  
Guillain Barré Syndrome ◽  
Viral Illness ◽  
Life Threatening ◽  
Depolarizing Agents ◽  
Guillain Barré

Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are both immune-mediated diseases of the peripheral nervous system that typically present with symmetric, progressive muscle weakness, areflexia, and sensory symptoms or signs. GBS evolves rapidly with a nadir at 2–4 weeks usually with an antecedent viral illness, while CIDP progresses more slowly over months to years. GBS is sometimes complicated by life-threatening respiratory failure or dysautonomia. Onset of GBS and relapse of CIDP can occur during pregnancy or postpartum. But with appropriate supportive care and immunotherapy, maternal and fetal outcome in both conditions is typically excellent. The exception is fetal outcome in GBS triggered by maternal CMV or Zika infection transmitted to the fetus. Full-term vaginal delivery and regional anesthesia are preferred in maternal GBS and CIDP, but if C-section and general anesthesia are indicated, non-depolarizing agents such as succinylcholine should be avoided.

Sign in / Sign up

Export Citation Format

Share Document